1.Study on drug properties of Arisaematis Rhizoma and Arisaema Cum Bile based on substance and energy metabolism in normal and cold/heat syndrome model rats.
Fa-Zhi SU ; Chen-Xi BAI ; Wen-Sen ZHANG ; Jing YANG ; Jian-Ping HU ; Yan-Ping SUN ; Bing-You YANG ; Hai-Xue KUANG ; Qiu-Hong WANG
China Journal of Chinese Materia Medica 2022;47(17):4682-4690
This paper clarified the scientific connotation of the changes in cold and heat properties of Arisaematis Rhizoma and Arisaema Cum Bile through investigating the changes of substance and energy metabolism after drug intervention in the rats with normal and cold/heat syndrome, so as to improve the method of evaluating the drug properties of Chinese medicine. After one week of adaptive feeding, healthy male SD rats were randomly divided into three parts: normal rats, heat syndrome rat models, and cold syndrome rat models. Through ice water bath and oral euthyrox(120 μg·kg~(-1)), the models of cold syndrome and heat syndrome were induced, respectively. The models were made at 9:00 am. and administrated by gavage at 3:00 pm. every day. All administration groups were administrated with Arisaematis Rhizoma and Arisaema Cum Bile decoction, respectively, and the blank group was given the same dose of normal saline. After continuous administration for 15 d, the rats were anesthetized by chloral hydrate, blood was taken from abdominal aorta, and the hearts and livers were removed and stored at-80 ℃. The changes in the body weight and anal temperature of rats during administration were detected, and the liver coefficient of rats was detected after removing the liver. Enzyme-linked immunosorbent assay(ELISA) was adopted to detect the expression level of the indexes related to substance and energy metabolism in liver and heart of rat, and Western blot was used to detect the expression of key proteins in AMPK/mTOR signaling pathway for further verification. The results showed that Arisaematis Rhizoma enhanced the expression level of enzymes related to substance and energy metabolism in the normal and cold and heat syndrome rat models, and increased anal temperature, which exhibited warm(hot) drug property. Arisaema Cum Bile inhibited the level of substance and energy metabolism in rats, and reduced anal temperature, which showed cold(cool) drug property. Chinese Pharmacopoeia has recorded "Arisaematis Rhizoma has warm property and Arisaema Cum Bile has cool property", which is consistent with the phenomenon in this study. Therefore, it is feasible to evaluate the drug properties of Chinese medicine based on the substance and energy metabolism of normal and cold/heat syndrome model rats, which completes the method of evaluating drug properties of Chinese medicine.
AMP-Activated Protein Kinases
;
Animals
;
Arisaema/chemistry*
;
Bile
;
Chloral Hydrate
;
Cold-Shock Response/drug effects*
;
Drugs, Chinese Herbal/therapeutic use*
;
Energy Metabolism
;
Heat Stroke/therapy*
;
Hot Temperature
;
Male
;
Rats
;
Rats, Sprague-Dawley
;
Saline Solution
;
Syndrome
;
TOR Serine-Threonine Kinases
;
Thyroxine
;
Water
2.Adverse Events and Risk Factors Associated with Chloral Hydrate Sedation for Brain Magnetic Resonance Imaging in the Neonatal Intensive Care Unit
Byeong Sub PARK ; Yeong Myong YOO ; O Kyu NOH ; Moon Sung PARK ; Jang Hoon LEE
Neonatal Medicine 2019;26(2):85-90
PURPOSE: This study investigated the incidence of adverse events (AEs) and risk factors associated with sedation using chloral hydrate (CH) for brain magnetic resonance imaging (MRI) in the neonatal intensive care unit (NICU). METHODS: This was a retrospective study of infants who received CH for brain MRI in the NICU. Among the enrolled infants (n=143), 12.6% (n=18) were included in the AE group and 87.4% (n=125) were in the non-adverse event group (NAE). RESULTS: Gestational age (GA) at birth and corrected GA at sedation were 35+0±7+2 and 39+5±3+1 respectively. The rate of AEs was 12.6%, included oxygen desaturation (5.6%), aspiration (4.9%), paradoxical agitation (0.7%), tachycardia or bradycardia (0.7%), and arrest (0.7%). In univariate analysis, the AE group was younger in corrected GA at sedation than the NAE group (37+2 [range, 36+0 to 40+0] vs. 40+1 [range, 38+2 to 41+4], P=0.015). There was no significant difference in CH dosage (50.0 [range, 50.0 to 50.0] vs. 50.0 [range, 50.0 to 50.0], P=0.092), cardiopulmonary (33.3% [n=6] vs. 17.6% [n= 22], P=0.209) and central nervous system (61.1% [n=11] vs. 65.6% [n=82], P=0.054) morbidity. In multivariate analysis, CH dosage was the only significant risk factor for AEs associated with sedation (odds ratio, 1.04; 95% confidence interval, 1.01 to 1.07; P=0.0186). CONCLUSION: AEs associated with sedation using CH are not uncommon and should be considered when using high dose CH for diagnostic testing in the NICU.
Bradycardia
;
Brain
;
Central Nervous System
;
Chloral Hydrate
;
Diagnostic Tests, Routine
;
Dihydroergotamine
;
Gestational Age
;
Humans
;
Incidence
;
Infant
;
Infant, Newborn
;
Intensive Care, Neonatal
;
Magnetic Resonance Imaging
;
Multivariate Analysis
;
Oxygen
;
Parturition
;
Retrospective Studies
;
Risk Factors
;
Tachycardia
3.Morroniside on anti-inflammation activities in rats following acute myocardial infarction.
Bangxing YU ; Guoxing ZHANG ; Yi AN ; Wen WANG
The Korean Journal of Physiology and Pharmacology 2018;22(1):17-21
Our previous studies have confirmed that morroniside has neuroprotective effects. However, the effects of morroniside on cardiac myocardium remain unknown. Rats were anaesthetized with 10% chloral hydrate (0.35~0.4 mL/kg) and an acute myocardial infarction (AMI) was induced by ligating the anterior descending coronary artery (LAD). Following AMI, morroniside was administered intragastrically for 3 consecutive days at doses of 45, 90 and 180 mg/kg, respectively. Lactate dehydrogenase (LDH) and cardiac troponin T (cTnT) activities in AMI rats in the serum were detected with commercial kits. The expression of IL-6, IL-1β and TNF-α in myocardium was detected by Western blotting analysis. We observed a significant decline in the Q(q) wave amplitude in morroniside-treated rats after 72 h. Additionally, treatment of morroniside decreased the levels of LDH and cTnT in AMI rats. We also observed that morroniside reduced the expression of IL-6, IL-1β and TNF-α in myocardium. Taken together, our findings demonstrate that morroniside had effective anti-inflammatory properties in AMI rats.
Animals
;
Blotting, Western
;
Chloral Hydrate
;
Coronary Vessels
;
Inflammation
;
Interleukin-6
;
L-Lactate Dehydrogenase
;
Myocardial Infarction*
;
Myocardium
;
Neuroprotective Agents
;
Rats*
;
Troponin T
4.The Changes of Sedation in the Department of Pediatric Dentistry, Yonsei University Dental Hospital
Koeun LEE ; Je Seon SONG ; Seong Oh KIM ; Jaeho LEE ; Byungjai CHOI ; Hyung Jun CHOI
Journal of Korean Academy of Pediatric Dentistry 2018;45(2):154-161
Sedation is a useful behavior management technique for dental patients who may be uncontrollable or have medical problems. The aim of this study is to investigate the changes in patterns of sedative treatments in pediatric dentistry by analyzing the distribution of patients and used sedative agents.Patients and sedative agents were reviewed based on the electronic medical records (EMR) of the department of pediatric dentistry in Yonsei University Dental Hospital from 2011 to 2016.The number of patients who were treated under sedation generally increased. Male received more sedation treatment than female by 2014, and they became similar from 2015. The treatment percentage of patients with systemic disease decreased in 2013, remained constantly afterwards. The ratio of sedative treatment for the age 4 – 5 and age 6 – 10 generally increased, while that of the age 0 – 2 and older than age 11 decreased. The ratio of the age 3 remained steady. Nitrous oxide was the most frequently used sedative agent. The use of benzodiazepine increased while the use of chloral hydrate decreased.Although the use of sedation has expanded, multidimensional approaches for ensuring safety have been less focused. Therefore, it is necessary to explore further studies for the safety and efficacy of the use of sedation.
Behavior Control
;
Benzodiazepines
;
Chloral Hydrate
;
Conscious Sedation
;
Electronic Health Records
;
Female
;
Humans
;
Male
;
Nitrous Oxide
;
Pediatric Dentistry
5.Comparison of sedation outcome according to the dose of chloral hydrate in children requiring laceration repair.
Bo Kyeong SEO ; Areum KIM ; Hyun Min JUNG ; Ah Jin KIM ; Seung Baik HAN
Pediatric Emergency Medicine Journal 2017;4(2):92-96
PURPOSE: To compare the sedation outcome according to the dose of per os chloral hydrate in children who underwent laceration repair in the emergency department (ED). METHODS: This retrospective study was performed to the children who underwent sedation using chloral hydrate for laceration repair in the ED from January 2015 through November 2015. A total of 370 children aged younger than 6 years underwent the sedation. We compared the induction time, duration of sedation, and ED length of stay (EDLOS) between the single dose (50 mg/kg) and additional dose (plus 25 mg/kg) groups. RESULTS: Of 370 children, 335 (90.5%) were sedated successfully, 284 (76.8%) were sedated with initial dose (the single dose group), and 51 (13.8%) were sedated with additional dose (the additional dose group). The induction time and EDLOS were longer in the additional dose group (induction time: 31.0 ± 17.2 minutes vs. 96.2 ± 25.4 minutes, P < 0.001; EDLOS: 137.2 ± 35.5 minutes vs. 193.0 ± 36.0 minutes, P < 0.001). The duration of sedation showed no difference between the 2 groups (44.4 ± 24.0 minutes vs. 42.0 ± 20.8 minutes; P = 0.500). No one had serious adverse reactions. CONCLUSION: Additional dose of chloral hydrate can increase the induction time and EDLOS without increasing the duration of sedation and causing serious adverse reactions. This information may improve the efficiency of ED workflow when shared with parents of the children.
Child*
;
Chloral Hydrate*
;
Conscious Sedation
;
Emergency Service, Hospital
;
Humans
;
Lacerations*
;
Length of Stay
;
Parents
;
Retrospective Studies
6.Comparison of Safety of Sedatives Versus General Anesthesia in Laser Therapy for Retinopathy of Prematurity.
Yo Han HO ; Jin Hwa CHOI ; Ji Sook KIM ; Se In SUNG ; So Yoon AHN ; Sang Jin KIM ; Yun Sil CHANG ; Won Soon PARK
Neonatal Medicine 2017;24(2):71-76
PURPOSE: Laser therapy for retinopathy of prematurity (ROP) is commonly performed under general anesthesia (GA). However, the use of GA for laser therapy in neonates who have already undergone invasive ventilation may lead to postoperative complications such as severe apnea or the development of ventilator dependency. This study aimed to examine the safety of administering only sedatives instead of GA in extremely low birth weight (ELBW) infants, who are the usual recipients of laser therapy for ROP. METHODS: Among ELBW infants who were admitted to the neonatal intensive care unit (NICU) at Samsung Medical Center between January and December 2012, we studied 30 patients treated with laser therapy for ROP. RESULTS: The mean gestational age of the patients was 24.6±1.9 weeks, with a mean birth weight of 646±140 g. The mean age and weight of patients at the time of laser therapy for ROP was 36.3±2.3 weeks and 1,470±423 g. In terms of sedatives, 14 patients (46.7%) were administered chloral hydrate alone, 14 (46.7%) were administered a combination of chloral hydrate and midazolam, one was administered midazolam alone, and one received fentanyl. Prior to laser therapy, 16 patients (53.5%) had established self-respiration, 13 (43.3%) relied on non-invasive ventilation and one patient relied on invasive mechanical ventilation. Following laser therapy, two patients who initially had exhibited self-respiration required respiratory assistance via non-invasive positive pressure ventilation and no patient required intratracheal intubation. CONCLUSIONS: We conclude that the use of sedatives may be safe for ELBW infants who undergo laser therapy for ROP.
Anesthesia, General*
;
Apnea
;
Birth Weight
;
Chloral Hydrate
;
Fentanyl
;
Gestational Age
;
Humans
;
Hypnotics and Sedatives*
;
Infant
;
Infant, Low Birth Weight
;
Infant, Newborn
;
Intensive Care, Neonatal
;
Intubation, Intratracheal
;
Laser Therapy*
;
Midazolam
;
Noninvasive Ventilation
;
Positive-Pressure Respiration
;
Postoperative Complications
;
Respiration, Artificial
;
Retinopathy of Prematurity*
;
Ventilation
;
Ventilators, Mechanical
7.Administration and Efficiency Comparison of Chloral Hydrate during Pediatric Sedation.
Jung Ah BAE ; Yoon Hee CHOI ; Ah Jin KIM ; Sun Hwa LEE
Journal of The Korean Society of Clinical Toxicology 2016;14(1):9-15
PURPOSE: In most emergency department (ED), sedation is required before carrying out an invasive procedure on a pediatric patient. In the ED setting, it is essential to determine the optimal dose and administration route of CH for successful sedation. The aim of this study was to determine the optimal dose of CH for an invasive procedure and to examine the effectiveness of the drug's different administration routes. Furthermore, in this study, we performed simple survey using questionnaire which composed of Likert-scale to evaluate satisfaction of medical staffs in ED with administration routes. METHODS: This study was conducted prospectively. The study participants were pediatric patients under 8 years old who visited the ED in two tertiary hospitals in South Korea within a period of 12 months. RESULTS: Overall, 300 patients were included in this study. The age, sex, and weight of the patients were not shown to influence the sedation time. Chloral hydrate dosage is the independent factor to influence the both sedation and discharge time (p<0.01). In the comparison of the groups, groups 1, 2, and 5 showed no significant difference. On the other hand, groups 3 and 4 were shown to be statistically significantly different from group 1. CONCLUSION: Up to 100 mg/kg CH is safe to use in the emergency department for pediatric patients, but the initial dose of 50 mg/kg for oral administration should be considered in advance because it can provide safe and effective sedation with a lower possibility of causing an adverse effect.
Administration, Oral
;
Chloral Hydrate*
;
Deep Sedation
;
Emergency Service, Hospital
;
Hand
;
Humans
;
Korea
;
Medical Staff
;
Prospective Studies
;
Tertiary Care Centers
8.Assessment of chloral hydrate-centered pediatric sedation performed by non-anesthesiologists.
Young Sung KIM ; Byung Gun LIM ; Sung Wook KANG ; So Hyun LEE ; Wonjoon LEE ; Il Ok LEE
Anesthesia and Pain Medicine 2016;11(4):366-374
BACKGROUND: We aimed to evaluate the efficacy and safety of chloral hydrate-based pediatric sedation conducted by non-anesthesiologists. METHODS: The design and setting of this study was a single-center retrospective study performed at a tertiary university hospital between July 2012 and May 2013. A total of 519 children were enrolled in this study. We investigated the sedation medication, age of patients and type of diagnostic tests or procedures and evaluated the success rate of sedation, sedation/recovery profiles and adverse events. RESULTS: Most patients underwent moderate sedation for diagnostic tests. The most commonly used sedative drug was chloral hydrate, which was solely used for 482 patients. A combination of chloral hydrate/midazolam was used for 24 patients and midazolam only was used for 13 patients. Use of chloral hydrate resulted in a sedation success rate of 65.5% after the initial dose and a success rate of 95.2% with additional doses. The sedation failure rate in children > 6 years was significantly higher than that in children under 6 years. In all patients, the overall onset time and recovery time were too slow and long, respectively, and there was no critical complication. CONCLUSIONS: This study demonstrated that chloral hydrate-based pediatric sedation conducted by non-anesthesiologists was mostly moderate, with a high success rate and a low complication rate. However, the overall onset time and recovery time were too slow and long, respectively. Especially, alternative sedation regimens are required in children > 6 years considering the slower onset time and higher failure rate of sedation.
Child
;
Chloral Hydrate
;
Conscious Sedation
;
Diagnostic Tests, Routine
;
Humans
;
Midazolam
;
Retrospective Studies
9.Considerations for submucosal midazolam administration in combination with oral and inhaled medications for sedation of pediatric dental patients.
Journal of Dental Anesthesia and Pain Medicine 2015;15(2):47-52
Sedation allows patients to maintain their airway independently and respond appropriately to physical stimulation and verbal command while maintaining a minimum depressed level of consciousness. Drugs commonly used for sedation of pediatric dental patients include a combination of chloral hydrate, hydroxyzine, and nitrous oxide-oxygen. Midazolam is a benzodiazepine and currently one of the most commonly used intravenous sedative agents. It can be easily titrated to provide a wide range of sedation, from conscious sedation to deep sedation, and exhibits a wide safety margin without severe respiratory and circulatory depression. At an appropriate dose, it also decreases patient anxiety and induces amnesia. We found that the submucosal administration of midazolam combined with chloral hydrate provided increased sedative effects and decreased the postoperative vomiting response compared with conventional chloral hydrate administration, with no significant difference in physiological responses. The depth of sedation can be titrated using this technique.
Amnesia
;
Anxiety
;
Benzodiazepines
;
Chloral Hydrate
;
Conscious Sedation
;
Consciousness Disorders
;
Deep Sedation
;
Depression
;
Humans
;
Hydroxyzine
;
Hypnotics and Sedatives
;
Midazolam*
;
Pediatric Dentistry
;
Physical Stimulation
;
Postoperative Nausea and Vomiting
10.The alternative of oral sedation for pediatric dental care.
Jongbin KIM ; Seungoh KIM ; Deok Won LEE ; Dae Seung RYU
Journal of Dental Anesthesia and Pain Medicine 2015;15(1):1-4
In pediatric dentistry, chloral hydrate is habitually selected for sedation of uncooperative children. Although chloral hydrate has been used for decades, various adverse effects are reported and necessity for new alternative drugs has increased. Dexmedetomidine was approved by FDA for sedation at intensive care units (ICU) in 1999. Compared to conventional sedative drugs, dexmedetomidine has not only analgesic and sedative effects but also it barely suppresses the respiratory system. Due to these characteristics, dexmedetomidine is known as safe sedative drug for children and elderly patients. Furthermore, approved by KFDA in 2010 in Korea, the frequency of sedation using dexmedetomidine is increasing. However, due to its intravenous administration method, it was difficult to apply in pediatric dentistry. Recently, intranasal administration method was introduced which might be a new possible alternative of oral sedation. In this study, we compare the mechanisms, pros and cons of chloral hydrate and dexmedetomidine, introducing new possibilities.
Administration, Intranasal
;
Administration, Intravenous
;
Aged
;
Child
;
Chloral Hydrate
;
Dental Care*
;
Dexmedetomidine
;
Humans
;
Hypnotics and Sedatives
;
Intensive Care Units
;
Korea
;
Methods
;
Pediatric Dentistry
;
Respiratory System

Result Analysis
Print
Save
E-mail